175 related articles for article (PubMed ID: 29734851)
1. Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer.
Xie Z; Cheng D; Luo L; Shen G; Pan S; Pan Y; Chen B; Wang X; Liu Z; Zhang Y; Ye F
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):905-919. PubMed ID: 29734851
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.
Zhu W; Chen H; Wang Y; Wang J; Peng X; Chen X; Gao Y; Li C; He Y; Ai J; Geng M; Zheng M; Liu H
J Med Chem; 2017 Jul; 60(14):6018-6035. PubMed ID: 28714692
[TBL] [Abstract][Full Text] [Related]
3. Discovery and anti-cancer evaluation of two novel non-ATP-competitive FGFR1 inhibitors in non-small-cell lung cancer.
Wu J; Wei T; Tang Q; Weng B; Li W; Jiang X; Ding T; Li X; Liang G; Cai Y; Ji J
BMC Cancer; 2015 Apr; 15():276. PubMed ID: 25880284
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, and Biological Evaluation of C-2 Substituted 3Hthieno[ 2,3-d]pyrimidin-4-one Derivatives as Novel FGFR1 Inhibitors.
Guo P; Xie Z; Zhang H; Zhang Z; Han C; Cheng D; Lin D; Zhang Y; Wang X; Guo X; Ye F
Med Chem; 2017; 13(8):753-760. PubMed ID: 28641527
[TBL] [Abstract][Full Text] [Related]
5. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.
Liu Z; Yu S; Chen D; Shen G; Wang Y; Hou L; Lin D; Zhang J; Ye F
Drug Des Devel Ther; 2016; 10():1489-500. PubMed ID: 27217720
[TBL] [Abstract][Full Text] [Related]
7. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
8. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models.
Zhang J; Zhang L; Su X; Li M; Xie L; Malchers F; Fan S; Yin X; Xu Y; Liu K; Dong Z; Zhu G; Qian Z; Tang L; Schöttle J; Zhan P; Ji Q; Kilgour E; Smith PD; Brooks AN; Thomas RK; Gavine PR
Clin Cancer Res; 2012 Dec; 18(24):6658-67. PubMed ID: 23082000
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer.
Ying S; Du X; Fu W; Yun D; Chen L; Cai Y; Xu Q; Wu J; Li W; Liang G
Eur J Med Chem; 2017 Feb; 127():885-899. PubMed ID: 27829519
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of biological and antitumor activities of 5,7-dimethyl- oxazolo[5,4-d]pyrimidine-4,6(5H,7H)-dione derivatives as novel inhibitors of FGFR1.
Ye F; Wang Y; Nian S; Wang Y; Chen D; Yu S; Wang S
J Enzyme Inhib Med Chem; 2015 Dec; 30(6):961-6. PubMed ID: 25683078
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of protein kinase C α/βII and activation of c-Jun NH2-terminal kinase mediate glycyrrhetinic acid induced apoptosis in non-small cell lung cancer NCI-H460 cells.
Song J; Ko HS; Sohn EJ; Kim B; Kim JH; Kim HJ; Kim C; Kim JE; Kim SH
Bioorg Med Chem Lett; 2014 Feb; 24(4):1188-91. PubMed ID: 24461294
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Biological Evaluation of 6-(2,6-Dichloro-3,5-dimethoxyphenyl)-4-substituted-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors.
Zhang Z; Zhao D; Dai Y; Cheng M; Geng M; Shen J; Ma Y; Ai J; Xiong B
Molecules; 2016 Oct; 21(10):. PubMed ID: 27782099
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo.
Wang XM; Xin MH; Xu J; Kang BR; Li Y; Lu SM; Zhang SQ
Eur J Med Chem; 2015; 96():382-95. PubMed ID: 25911625
[TBL] [Abstract][Full Text] [Related]
14. Acenaphtho[1,2-b]pyrrole-based selective fibroblast growth factor receptors 1 (FGFR1) inhibitors: design, synthesis, and biological activity.
Chen Z; Wang X; Zhu W; Cao X; Tong L; Li H; Xie H; Xu Y; Tan S; Kuang D; Ding J; Qian X
J Med Chem; 2011 Jun; 54(11):3732-45. PubMed ID: 21517068
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, in-vitro antiproliferative activity and kinase profile of new picolinamide based 2-amido and ureido quinoline derivatives.
El-Damasy AK; Seo SH; Cho NC; Kang SB; Pae AN; Kim KS; Keum G
Eur J Med Chem; 2015 Aug; 101():754-68. PubMed ID: 26218653
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of N-phenylsulfonylnicotinamide derivatives as novel antitumor inhibitors.
Zhang H; Lu X; Zhang LR; Liu JJ; Yang XH; Wang XM; Zhu HL
Bioorg Med Chem; 2012 Feb; 20(4):1411-6. PubMed ID: 22277588
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
18. Discovery and identification of new non-ATP competitive FGFR1 inhibitors with therapeutic potential on non-small-cell lung cancer.
Wang Y; Cai Y; Ji J; Liu Z; Zhao C; Zhao Y; Wei T; Shen X; Zhang X; Li X; Liang G
Cancer Lett; 2014 Mar; 344(1):82-89. PubMed ID: 24513267
[TBL] [Abstract][Full Text] [Related]
19. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
20. Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors.
Shan Y; Wang C; Zhang L; Wang J; Wang M; Dong Y
Bioorg Med Chem; 2016 Feb; 24(4):750-8. PubMed ID: 26753815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
